Camurus faces USFDA rejection on Acromegaly drug CAM2029
The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly.
Written By : Farhat Nasim
Published On 2024-10-23 10:51 GMT | Update On 2024-10-23 10:51 GMT
Advertisement
Bengaluru: The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugmaker said late Monday.
The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly, which is diagnosed in three to 14 of every 100,000 people.
The decision is "disappointing, however, we are confident in the data supporting our NDA and the potential of CAM2029 to address unmet medical needs of patients with acromegaly," Camurus CEO Fredrik Tiberg said.
Camurus' shares plummeted by 10% in Stockholm trade following the decision.
The manufacturing issues could delay the approval of Oclaiz for six months to one year, pushing its launch to the fourth quarter of 2025, according to Jefferies analysts.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.